Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation Trial

INTERVENTION: Examination of the study hypothesis in a prospective, randomized, placebo‐controlled, double‐blind group comparison in patients with documented paroxysmal atrial fibrillation. 40 mg/day Olmesartanmedoxomil versus Placebo. CONDITION: Paroxysmal Atrial Fibrillation ; Circulatory System ; Atrial fibrillation PRIMARY OUTCOME: Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele‐ECG recording) SECONDARY OUTCOME: 1. Time to first occurrence of a documented relapse of atrial fibrillation; 2. Time to first occurrence of a symptomatic documented episode of AF; 3. Time to persistent atrial fibrillation; 4. Time to prescription of the recovery‐medication; 5. Number of hospitalizations for cardiovascular reasons (‐> Endpoint review); 6. Number of intermediate medical visits for cardiovascular reasons (‐> Endpoint review) without hospitalization; 7. Number of cerebrovascular events; 8. Quality of life INCLUSION CRITERIA: 1. Documented paroxysmal atrial fibrillation: electrocardiogram (ECG) documentation of atrial fibrillation at least in one ECG recorded during the last 2 months prior to randomization plus additional ECG recording of sinus rhythm at least 12 hours after the above mentioned ECG documentation 2. Age =18 3. Patient informed orally and in writing 4. Written informed consent of the patient